Search for: "Merck, Sharpe "
Results 221 - 240
of 262
Sorted by Relevance
|
Sort by Date
21 Dec 2017, 7:09 am
This work will encompass multiple research projects with the current proposals looking at: the role of price differentials, sector specific impacts and enforcement impacts.BREAKING: CJEU holds that SPCs cannot be obtained on the basis of an "end of procedure notice" pursuant to Article 3(b) SPC RegulationMr Justice Arnold referred two questions to the CJEU on the SPC Regulation in Merck Sharp & Dohme v Comptroller-General of Patents [2016] EWHC… [read post]
17 Feb 2010, 5:10 am
Merck, Sharp & Dohme Corp. [read post]
16 Jun 2010, 3:02 pm
(Patent Docs) Cubicin (Daptomycin) – US: Cubist Pharmaceuticals to oppose Teva’s attempt to add inequitable conduct defense in patent infringement action (SmartBrief) Dorzolamide/Timolol – Netherlands: Preliminary injunction judge rules UK invalidity decision not sufficient to rule non-negligible chance that (Dutch part of) patent will be invalidated in proceedings on the merits: Merck Sharp & Dohme v. [read post]
3 Aug 2011, 3:31 am
General EU – India agreement in WTO dispute raises bar for EU drug seizures (IP Watch) EU: CJEU rules on repackaging of pharma goods: Joined Cases C-400/09 and C-207/10 Orifarm and Paranova v Merck Sharp Dohme (Class 46) (IPKat) EU: Ophtal v Oftal Cusi- General Court upholds finding of no likelihood of confusion for identical goods in T-160/09 (Class 46) EU: The holiday is over: a close reading of the opinion in Medeva: Joined Cases C? [read post]
13 Feb 2023, 2:40 pm
EU/1/15/1024 for pembrolizumab, granted to Merck Sharp & Dohme. [read post]
7 Jul 2021, 11:44 pm
The Patentees filed two PTE applications, each of which was based on different goods on the ARTG: Brand Name OPDIVO® KEYTRUDA® Active ingredient nivolumab pembrolizumab Australian sponsor Bristol-Myers Squibb Australia Pty Ltd Merck Sharp & Dohme (Australia) Pty Ltd Relationship between sponsor and patentees Related to one of the patentees Not related to either patentee Date goods containing the drug were first included on ARTG 11 January 2016 16 April 2015 Duration… [read post]
3 Jun 2019, 11:26 am
In Merck, Sharp & Dohme Corp., 367 NLRB No. 122 (May 7, 2019), the employer has 23,000 employees in the United States, approximately 2700 of whom are represented by various unions in different plants. [read post]
28 Jun 2018, 1:42 pm
McCarthy & Holtus: Whether the Fair Debt Collection Practices Act applies to nonjudicial foreclosure proceedings; and Merck Sharp & Dohme v. [read post]
24 Feb 2010, 2:11 am
Co. v Doll (Filewrapper) US: District Court Massachusetts denies bid for bench trial in RNAi patent suit: Max-Planck-Gesellschaft v Whitehead Institute for Biomedical Research (Patent Docs) US: Court of Appeal for the Ninth Circuit: Federal jurisdiction found in Neuralstem v Reneuron (Patent Docs) US: District Court New Jersey: Disqualification of counsel in patent case requires ‘factual analysis’, not ‘automatic disqualification rule’: Wyeth et al v Abbott Laboratories et al… [read post]
18 Mar 2010, 2:30 am
(Patent Docs) Atripla (Emtricitabine) - US: District Court S D New York: Patent infringement suit filed following a Paragraph IV Certification: Merck, Sharp & Dohme Corp. et al. v. [read post]
2 Nov 2020, 2:00 am
Merck Sharp & Dohme Limited (MSD) sought to invalidate Wyeth LLC’s (Wyeth) patent, EP (UK) 2 676 679 (the ‘Patent’), with Wyeth maintaining that the Patent was valid and counterclaiming for infringement on a quia timet basis in relation to MSD’s V114 product. [read post]
13 Dec 2018, 4:05 pm
MSD’s (combination) SPCs The bitter taste of the CoA’s decision was in this case for Merck Sharp & Dome (‘MSD’). [read post]
24 Feb 2010, 2:11 am
Co. v Doll (Filewrapper) US: District Court Massachusetts denies bid for bench trial in RNAi patent suit: Max-Planck-Gesellschaft v Whitehead Institute for Biomedical Research (Patent Docs) US: Court of Appeal for the Ninth Circuit: Federal jurisdiction found in Neuralstem v Reneuron (Patent Docs) US: District Court New Jersey: Disqualification of counsel in patent case requires ‘factual analysis’, not ‘automatic disqualification rule’: Wyeth et al v Abbott Laboratories et al… [read post]
23 Dec 2020, 5:31 am
The AmeriKat has her mittens onin time for the cold, wintertradition of the AIPPI patentroundupA couple of weeks ago, instead of descending upon the hospitality of Hogan Lovells' London offices to devour patent law and mince pies, AIPPI UK members instead virtually attended the annual tradition that is the AIPPI UK Patent Cases Roundup. [read post]
23 Sep 2022, 9:39 am
selected address issues such as SPC protection for combination products, double patenting, prosecution history estoppel and the influence of declarations made by the patentee in parallel proceedings, the possibility for national courts to request technical opinions from the EPO under Art. 25 EPC, and the disappearance of the cautio iudicatum solvi that was sometimes required from foreign plaintiffs launching (patent) proceedings in Belgium.SPC’s for combination products: still more questions… [read post]
13 Aug 2015, 10:56 am
Today we have a guest post (her second - she's a glutton for punishment) from fellow Reed Smith associate Danielle Devens. [read post]
29 Jul 2016, 1:30 pm
This term has been no different, but my, how they have ended in a dramatic fashion with....drum roll please...a reference to the CJEU from Mr Justice Arnold on the SPC Regulation in Merck Sharp & Dohme v Comptroller-General of Patents [2016] EWHC 1896.The problem and the questions to be referred What do you do if your patent is about to expire, but despite notice that Member States have agreed to grant your marketing authorization (MA) under the decentralized… [read post]
29 Nov 2009, 3:13 pm
That’s a sharp departure from how the CBO treated similar mandates in the Clinton health plan. [read post]
11 Nov 2010, 12:54 pm
Merck & Co., 2003 WL 22902622, at *3 n.3 (E.D. [read post]
25 Jun 2018, 5:39 pm
Merck Sharp & Dohme Corp v. [read post]
